You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 756 INCLINE-101, a phase 1/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
756 INCLINE-101, a phase 1/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2024

AbstractFullPdf
Nov 2022292014
Dec 2022108010
Jan 20237808
Feb 2023104012
Mar 20239605
Apr 20234608
May 20236209
Jun 202396012
Jul 20234207
Aug 20235007
Sep 20236405
Oct 202311006
Nov 20238207
Dec 20235403
Jan 20246203
Feb 20243605
Mar 20245609
Apr 20245206
May 20246806
Jun 20245403
Jul 20244207
Aug 20245404
Sep 20246007
Total17680163